Overview

NCI Definition: A malignant B-cell lymphoproliferative process affecting the blood, bone marrow, and spleen. The B-prolymphocytes are medium-sized, round lymphoid cells with prominent nucleoli. The B-prolymphocytes must exceed 55% of lymphoid cells in the blood. Cases of transformed chronic lymphocytic leukemia (CLL) and CLL with increased prolymphocytes are excluded. The prognosis is poor. (WHO, 2001) [1]

Significant Genes in B-Cell Prolymphocytic Leukemia

ABL1 +

AFF1 +

BCR +

DEK +

ELL +

FLT3 +

IKZF1 +

KMT2A +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

NPM1 +

NUP214 +

PBX1 +

RPN1 +

TCF3 +

TP53 +

Disease Details

Synonyms
B Prolymphocytic Leukemia
Parent(s)
Prolymphocytic Leukemia
OncoTree Name
B-Cell Prolymphocytic Leukemia
OncoTree Code
BPLL

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.